ロード中...
Loss of BOP1 confers resistance to BRAF kinase inhibitors in melanoma by activating MAP kinase pathway
Acquired resistance to BRAF kinase inhibitors (BRAFi) is the primary cause for their limited clinical benefit. Although several mechanisms of acquired BRAFi resistance have been identified, the basis for acquired resistance remains unknown in over 40% of melanomas. We performed a large-scale short-h...
保存先:
| 出版年: | Proc Natl Acad Sci U S A |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
National Academy of Sciences
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6410847/ https://ncbi.nlm.nih.gov/pubmed/30782837 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1821889116 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|